Reports that two children died after receiving gene-editing treatments in separate clinical trials in China have drawn intense scrutiny to the country’s fast-track trial pathway. In response, the government has intensified regulation to ensure a balance between biomedical innovation and patient safety.
Investigator-initiated trials (IITs) have become a prevalent method for researchers and biotech firms to evaluate new therapies. These trials are significantly quicker than the formal drug-approval processes managed by the National Medical Products Administration, which functions similarly to the US Food and Drug Administration. IITs are widely regarded as a key factor in China’s growing competitiveness in biomedicine, particularly within the cell and gene therapy sectors. The number of annually registered IITs in these fields increased elevenfold, reaching 207 between 2015 and 2023.
The tragic deaths occurred just months after the implementation of Order 818 on 1 May, a regulatory framework designed to impose stricter oversight on IITs involving novel biomedical technologies such as gene editing, brain implants, and cell therapies.
Under the previous regulatory environment, while rules existed requiring stem-cell therapies to be conducted at _sanjia_—China’s highest-tier research hospitals—enforcement was lax. According to Iris Zhang, a lawyer at Han Kun Law Offices in Shanghai, much of the cell-therapy activity occurred in non-_sanjia_ institutions, private clinics, and hospital-affiliated ventures. This inconsistent supervision fostered a grey market where companies and hospitals sometimes charged exorbitant fees for unauthorized or fraudulent treatments, leading to medical accidents and fatalities.
Order 818 now restricts the conduct of IITs for all new biomedical technologies exclusively to _sanjia_ hospitals. Ruby Wang, a physician and China health-policy consultant based in London, noted that these institutions possess the most reliable clinicians and researchers, providing essential safeguards for patients.
While previous rules required IITs to pass scientific and ethical assessments at the hospital level and register with the National Health Commission (NHC), the new order introduces additional layers of oversight. The NHC may conduct a second round of assessments and holds the authority to suspend, alter, or cancel trials if technical or ethical issues arise. Aaron Gu, also a lawyer at Han Kun Law Offices, described this new filing system as resembling a de-facto approval process.
For the first time, the regulations include significant penalties for violations. Hospitals or companies found conducting unauthorized clinical trials face fines of millions of yuan, a three-year ban from carrying out trials on new biomedical technologies, and potential revocation of medical licenses for the physicians involved.
Hao Bin, an economist at Xi’an Jiaotong-Liverpool University in Suzhou, stated that the order aims to increase regulatory oversight of these high-stakes trials. However, Lizzi Lee, a researcher at the Asia Society Policy Institute, cautioned that the real impact depends on consistent implementation. She warned that inconsistent enforcement could erode public trust, whereas overly strict application might hinder innovation.
Elevenfold increase in trials is impressive, but safety oversight was clearly lagging behind the hype.
Finally! The grey market has been dangerous for years. Hopefully consistent enforcement prevents future tragedies.
Is banning non-top-tier hospitals really safe? Desperate families might just seek unregulated clinics abroad instead.
Tough regulations are needed after children died. Innovation cannot come at the cost of lives.